Trials / Completed
CompletedNCT00150787
Monotherapy With Levetiracetam or Carbamazepine in Patients Suffering From Epilepsy.
A Multicenter, Double-blind, Follow-up Trial Evaluating the Long-term Safety of Levetiracetam (1000 to 3000 mg/Day Oral b.i.d.) and Carbamazepine (400 to 1200 mg/Day Oral b.i.d.), Used as Monotherapy in Subjects (≥ 16 Years) Coming From the N01061 Trial.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 250 (planned)
- Sponsor
- UCB Pharma · Industry
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- —
Summary
A double-blind follow-up trial assessing the long term safety of Levetiracetam as per adverse events reporting, physical and neurological examination and vital signs
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LEVETIRACETAM |
Timeline
- Start date
- 2003-07-01
- Primary completion
- 2005-11-01
- Completion
- 2005-11-01
- First posted
- 2005-09-08
- Last updated
- 2013-11-26
Source: ClinicalTrials.gov record NCT00150787. Inclusion in this directory is not an endorsement.